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ABSTRACT: Background: Neuromelanin is a pigment
with strong iron-chelating properties preferentially found
in dopaminergic neurons of the substantia nigra pars
compacta (SNpc). Parkinson’s disease is characterized by
pronounced, MRI-detectable neuromelanin loss, but
the neuroprotective or neurotoxic role of neuromelanin
remains debated. Histological studies have demonstrated
neuromelanin increases with age, but this has not been
conﬁrmed in vivo, and there is uncertainty whether neuro-
melanin declines, stabilizes, or increases from middle age.
Methods: This study aimed to establish physiological
changes of pigmentation of the SNpc using a pooled data
set of neuromelanin-sensitive 3T MRI from 134 healthy
individuals aged 5-83 years. Neuromelanin-related bright-
ness (regional contrast to ratio) and calibrated hyperin-
tense volumes were analyzed using linear and nonlinear
regression models to characterize age effects. Laterality,
sex, and subregional effects were also assessed.
Results: For brightness, age effects were best described
as a quadratic trajectory explaining 81.5% of the
observed variance in the SNpc showing a strong
increase from childhood to adolescence, with plateauing
in middle age and a decline in older age. Similar but less
pronounced effects were seen in hyperintense volumes.
We also show an anterior-posterior gradient in SNpc
contrast, larger normalized neuromelanin-rich volume in
women > 47 years old, but no laterality effect.
Conclusions: Using optimized neuromelanin MRI in a life
span sample, we demonstrate a strong age effect with
inverted U-shaped SNpc pigmentation-related contrast
from childhood to old age. This age trajectory of physio-
logical SNpc pigmentation needs to be taken into
account for diagnostic applications of depigmentation.
The study also paves the way for systematic investiga-
tions of the mechanisms of neuromelanin in healthy and
pathological brain development and aging. © 2018 Inter-
national Parkinson and Movement Disorder Society
Neuromelanin (NM) is a dark pigmented granule pref-
erentially found in catecholaminergic neurons, such as
the substantia nigra (SN) and locus coeruleus (LC). NM
acts as a scavenger that removes excess potentially toxic
substances through the autooxidation of catecholamines
and/or binding redox-active metal ions.1 Given this
capacity to bind toxins and in particular ferric iron, NM
may be neuroprotective,2 but when released from degen-
erating neurons, it may also induce immune-based path-
ogenic mechanisms and trigger neurodegeneration.3,4
Parkinson’s disease (PD) has been hypothesized to
result from accelerated aging because of exacerbation
of oxidative stress in the SN in addition to environmen-
tal toxins in which NM plays an essential and catalytic
role.5 Neuromelanin chelated with ferric iron has para-
magnetic properties with subsequent T1 shortening.6,7
High-resolution short–echo time T1-weighted MRI
scans with additional magnetization transfer contrast
allows reliable and sensitive detection of paramagnetic
neuromelanin in the SN pars compacta and locus
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
*Correspondence to: Dorothee Auer; E-mail: Dorothee.Auer@nottingham.
ac.uk
Funding agencies: This work was supported by Parkinson’s UK
[grant number J-1204]; the Engineering and Physical Sciences
Research Council [grant number EP/R512849/1] through the Global
Challenges Research Fund- University of Nottingham, who funded
recruitment and MRI scanning of the adult participants, Multiple Sclero-
sis Society, and AT Children’s Project, and Action for AT who funded
recruitment and scanning of the child participants.
Relevant conﬂicts of interest/ﬁnancial disclosures: Y.X. is
funded by Parkinson’s UK. S.H.A is funded by the Ministry of
Higher Education, Malaysia.
Received: 16 April 2018; Revised: 12 July 2018; Accepted: 8 August 2018
DOI: 10.1002/mds.27502
Movement Disorders, 2018 1
coeruleus.8-10 The corresponding T1 hyperintensity is
considered to reﬂect the amount of ferric iron bound to
NM.11,12 In the context of PD and other neurodegener-
ative diseases, previous NM imaging has consistently
reported a reduction of T1 hyperintensity in the SN
and LC, and a link between symptom severity and
quantitative measures of neuromelanin loss.8,13-17
Robust normalization and quantiﬁcation procedures
were developed for scanner- and protocol-independent
data analysis as a prerequisite for multicenter trials and
clinical applications.16-18 One potential limitation of
these studies is the lack of detailed understanding of the
physiological variation of SN pigmentation in vivo
across the life span. Previous histological studies found
pigmented granules in human SN at around the age of
2-3 years, with accumulation as age increased.19 The size
and number of granules remained stable after the second
decade of life,20 whereas other studies reported an age-
dependent loss21-23 or a continued increase.24 The pre-
clinical evidence based on animal studies is very limited
because NM is hardly expressed in nonprimate brains.25
Using NM-sensitive MRI, an early in vivo MRI study
suggested a nonlinear age effect for human LC.26 How-
ever, in vivo characterization of the physiological
changes of the NM-related signal in the SN and its sub-
regions during brain development and age-related degen-
eration is lacking. This study aimed to investigate age-
related NM signal variation in the SN as well as other
physiological factors using optimized neuromelanin-
sensitive MRI in a comprehensive life span sample.
Material and Methods
Participants
This retrospective study pooled data of healthy partici-
pants across several prospectively recruiting studies with
Research Ethics Committee approval conducted within
our institution, as detailed in the supplementary mate-
rial. All participants aged 16 years and older gave
informed consent, and consent was provided by the par-
ent or guardian for participants younger than 16 years.
Data were collected from February 2015 to May 2018,
and 134 healthy control volunteers who were free from
major neurologic, psychiatric, or medical disorders were
included (for details, see the inclusion and exclusion cri-
teria in the supplementary Materials and Methods).
Imaging Acquisition
All participants underwent MRI using a 3T GE scanner
(Discovery MR750; GE Healthcare, Milwaukee, WI) with
a 32-channel head coil. The head was stabilized with
inﬂated foam padding. First, conventional sagittal T1
images were obtained for setting up the scanning ﬁeld. The
30-dimnesional spoiled gradient recalled neuromelanin-
sensitive T1-weighted images with magnetization transfer
were acquired with the following parameters that were
optimized on the basis of a previous protocol27: TR, 38.4
milliseconds; TE, 3 milliseconds; ﬂip angle, 20; slice thick-
ness, 2 mm; Field of view (FOV), 19.2; matrix:
480 × 192; scanning time, 3.25 minutes. Thirty axial
image slices were obtained on each individual with parallel
alignment to the anterior callosum-posterior callosum line.
Image Processing
We ﬁrst chose the 3 slices that contained substantia
nigra by ﬁrst identifying the red nuclei as landmarks
and then chose the 3 slices below that slice. In-house
Matlab-based semiautomated approaches were used to
compute (1) the contrast-to-background ratio (CBR)
and (2) the suprathreshold hyperintense volume of the
neuromelanin-rich region (a fully manual version of the
same method is described in reference 17, and the delin-
eation of ROIs is described in the supplementary mate-
rial and illustrated in Supplementary Fig. 2).
To calculate the CBR of bilateral SNs, 2 ROIs were
semiautomatically placed in the visually brightest-appearing
anterior and posterior SNs on each side on 3 consecutive
slices. Speciﬁcally, once the center of the region of interest
(ROI) was manually determined, this allowed for auto-
matic placement of 2 circles of 3-mm radius in the anterior
and posterior parts of the hyperintensity area of the left
and right SNs, respectively (inset of Supplementary Fig. 2).
Using the same approach, 2 control ROIs (5-mm radius
circles) were chosen to deﬁne the background signal in the
area of cerebral peduncles. We then derived the mean CBR
of the left and right SNs, and the anterior and posterior
SNs using the mean intensity of each ROI in the SN and
the average intensity of the 2 control background ROIs.
We measured the CBR using the following equation:
CBR= ðSISN-SIBGÞ=SIBG,
where SISN is the average signal intensity of semiauto-
matically deﬁned ROIs in the SN and SIBG as the mean
background signal intensity of the 2 background ROIs
chosen in the cerebral peduncles.
To compute hyperintense SN volumes, we followed the
approach described in reference 17 to select an optimized
calibration factor (Calopt) accounting for the protocol-
speciﬁc signal intensity and contrast variation. The study-
speciﬁc calibration factor was found through step-wise
variation of a multiplier (between 1 and 8.25, 0.25 incre-
ments) of the individual background (BG) noise term
expressed as SD of the signal intensity (SI) of the back-
ground region. Derived mean NM volumes for the adult
group’s mean only were compared with expected pigmen-
ted NM volume based on a recent histologic study of sub-
jects with a similar age range (ie, 172.8 ± 34.1 mm3,22;
see supplementary material and Supplementary Fig. 2 for
details). Individual thresholds were then determined as
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SIthre = SIBGmean + ðCalopt: × SDBGÞ,
where SIBGmean is the mean background signal intensity
of the 2 background ROIs (and the same average signal
of the background ROIs in each slice obtained for the
calculation of CBR) and SDBG is the standard deviation
of the background signal intensity.
Examples from different age groups are illustrated in Sup-
plementary Figure 3. We then visually inspected all seg-
mented volumes (blinded to age and sex) to conﬁrm that
suprathreshold voxels were within the boundary of the
SN. The boundary had to be redeﬁned if structures other
than the SN were included. Hyperintense SN volumes were
then calculated as the number of validated suprathreshold
voxels across 3 slides multiplied by the voxel size. Finally, to
control for the potential impact of developmental and invo-
lutional changes in brain and midbrain volume, we normal-
ized the hyperintense SN volume to the midbrain volume
using another in-house Matlab script that enabled freehand
drawing of the boundary of the midbrain area over the
3 selected slides (examples in Supplementary Fig. 3).
Based on visual inspection of the age-dependence of
the NM signal, we divided the population into 3 age
groups (<20, 20-47, and >47 years) for post hoc ana-
lyses. We then tested for age associations within these
3 subgroups using linear regression and group compari-
sons to quantify changes of SN volume and brightness
during development, adulthood, and middle-old age.
Half of both the volumetric and the CBR values were
randomly selected and repeated by the same viewer
(S.A., 2 years’ experience) and a second viewer blindly
(Y.X., 8 years of experience in brain-imaging research)
to derive the intraclass and interclass reliability. Intrara-
ter reliability of midbrain volumes was assessed in
three-quarters of the cases, and intraclass reliability was
examined. Statistical tests were performed using IBM-
SPSS for Windows (version 21.0; IBM, Armonk, NY).
For the main research question on the type of age depen-
dence of the NM signal, we used linear and nonlinear
regression analyses for volume and contrast ratios. The R2
values of these regression analyses after adjusting for the
number of variables in the model (adjusted R2) were com-
pared to assess which regression equation best described
the relationship between age and NM content in SNpc.
For comparison of NM volume and contrast ratios
between sexes, hemispheres (left vs right), and subregional
differences of CBR in SN (anterior vs posterior), we con-
ducted univariate or multivariate analyses of variance with
least-squares differences post hoc comparison or t tests.
Because sex was not completely matched in all age
groups (Supplementary Fig. 1), we also compared (post
hoc) NM volume and CBR between men and women in
each of the 3 age groups. Further post hoc tests were
undertaken based on visually deﬁned age subgroups and
to conﬁrm putative threshold dependence for the young
cohort. Where data were not normally distributed, we
applied nonparametric tests. Signiﬁcance was deﬁned at
α = 0.05. Values are given as mean ± standard deviation
unless stated otherwise. Intraclass and interclass correla-
tion coefﬁcient analyses were performed.
Results
Data from 5 participants (4%, including 3 children
and 2 adults > 65 years old) had to be excluded because
of movement artifacts after visual inspection. The ﬁnal
analysis thus included 129 healthy participants aged 5.1
to 82.7 years (mean age ± SD, 40.5 ± 24.3 years; 56 males
and 73 females). Figure 1 in the supplementary material
illustrates the distribution of age and sex of our cohort.
The intraclass and interclass correlation coefﬁcients for
intrarater and interrater concordance of SNpc suprathres-
hold volumes were 0.921 (95% CI, 0.867-0.953) and
0.913 (95% CI, 0.854-0.948), and those of SN-CBR were
0.985 (95% CI, 0.975-0.991) and 0.937 (95% CI,
0.895-0.963). The intraclass correlation coefﬁcient for
midbrain volumes was also very high (0.966; 95% CI,
0.835-0.987).
Age Effects of the Contrast-to-Background
Ratio of the Pigmented Substantial Nigra and
Its Subregions
Visual inspection (Fig. 1) shows a rapid increase in
the CBR of SNpc in those up to 20 years of age, with a
slow increase and a plateau between about 45 and
53 years of age, followed by a decrease with increasing
age. We also observed increased intersubject variability
with older age.
All the nonlinear ﬁtting approaches showed sig-
niﬁcant correlations between age and SN-CBR
FIG. 1. SN contrast-to-background noise ratio versus age (open circles)
in normal healthy participants (dashed lines represent 95% conﬁdence
intervals).
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(P < 0.0000001); see Supplementary Figure 4.
However, the quadratic regression demonstrated
the simplest ﬁtting curve with a high adjusted R2
(0.81). The equation was as follows: Y = -
0.0001X2 + 0.0065X + 0.1101 (Fig. 1). Life span
trajectories of NM contrast changes were similar in
both the anterior and posterior SNs, with an
adjusted R2 of 0.82 and 0.74 (P < 0.0000001).
Post hoc tests: Based on the qualitative assessment,
we further assessed the age effects across and within the
3 formed subgroups (see supplementary material).
Age Effect on the Pigmented SN Volume
The qualitative assessment suggests a similar but more
dispersed age trajectory for pigmented SN volumes com-
pared with those we found for SN CBR (Fig. 1).
Again, on the basis of the qualitative assessment, we
examined the age effect for 3 subgroups. Our results
showed there was a signiﬁcant age effect (1-way analysis
of variance) across the 3 age groups (Table 1 summarizes
the mean ± SD of each group and the signiﬁcance of their
comparisons) showing that the normalized pigmented SN
volume in the 20- to 47-year group was signiﬁcantly
higher than those >47 years, as well as those in the youn-
gest group old). Also, there was a difference in pigmented
SN volume in the >47-years-old group versus the
<20-years-old group. Figure 2 illustrates our ﬁndings of
signiﬁcant linear age effects on the normalized suprathres-
hold NM volume in children to adolescents < 20 years
old (R = 0.50; P = 0.0011) and also signiﬁcant, but
reversed age effects in those > 47 years old (R = 0.28;
P = 0.031), with data ﬁtted by 2 lines, Y = 0.0041X -
0.0108 and Y = -0.0007X + 0.0782, controlling for sex.
From 47 years old, we found a 5.3% loss per decade of
life, calculated from CBR values averaged over each
decade, and 3.9% loss when estimated using our CBR lin-
ear ﬁtting. No signiﬁcant age effects were seen between
20 and 47 years old (P = 0.38).
Sex, Laterality, and Subregional Effects on
Substantia Nigra Pigmentation
The normalized volume of the pigmented SN in females
was signiﬁcantly larger than in males in the oldest age
group (males, 0.027 ± 0.022; females, 0.039 ± 0.024;
P = 0.024). No other difference in volume or CBR was
found between the sexes (P = 0.79).
In addition, no laterality effect was found for either nor-
malized SN volume or CBR. The left pigmented normal-
ized SN volume (0.016 ± 0.012 mm3) was similar to the
right SNpc (0.018 ± 0.013 mm3); P = 0.406. The CBR
was also bilaterally similar (left SNpc, 0.231 ± 0.052;
right SNpc, 0.236 ± 0.053; P = 0.293). However, across
the life span, the anterior SN (0.253 ± 0.057) displayed
higher CBR than the posterior SN (0.209 ± 0.048);
P < 0.0000001 (Fig. 3). We further assessed any coil
inhomogeneities that might affect the laterality effect but
found no signiﬁcant differences when comparing the
mean intensities within the left and right background
ROIs (P > 0.05).
Discussion
NM-sensitive MRI in a large, comprehensive life span
sample of healthy volunteers demonstrated that SN pig-
mentation steeply increases from early childhood to
young adulthood, plateaus in middle age, and declines
in the sixth decade following an inverted U-shaped
TABLE 1. Summary of pigmented SN related metrics for the three age subgroups
Age group (total:female) <20 (41:22) 20-47 (27:14) >47 (61:38) One-way ANOVA Pairwise comparisons (P)
Value × 100 (Mean ± SD) <20 vs 20-47 <20 vs > 47 20-47 vs > 47
Normalized volume 2.0 ± 1.8 5.2 ± 2.5 3.5 ± 2.2a < 0.000001 < 0.0001 0.004
CBR total–SNpc 17.5 ± 3.8 25.4 ± 2.2 26.3 ± 2.9a < 0.000001 < 0.000001 0.09
CBR Ant–SNpc 19.2 ± 4.0 27.3 ± 2.5 29.4 ± 3.3a < 0.000001 < 0.000001 0.0064
CBR post–SNpc 15.9 ± 3.8 23.3 ± 2.5 23.0 ± 3.4a < 0.000001 < 0.000001 0.8193
asigniﬁcant group difference, p < 0.000001.
FIG. 2. Linear age effects on the normalized suprathreshold NM volume
in the 3 age subgroups (for the sake of illustration, demonstrated values
in Y axis are the real normalized suprathreshold volume multiplied by
100). [Color ﬁgure can be viewed at wileyonlinelibrary.com]
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trajectory. Brightness was best described by a quadratic
ﬁt, with contrast ratios yielding a signiﬁcantly better ﬁt
than volume, explaining 81.5% of the variance.
Regional differences were found, with brighter anterior
versus posterior SN across all ages.
Neuromelanin Strongly Increases in Childhood
and Young Adulthood
Using an optimized NM-sensitive MRI and custom
scan preparation (https://www.youtube.com/watch?
v=IMpfW8KtoE8),28 we visualized the NM-rich
region in the SN in vivo in young children from
5 years as the earliest age when sedation-free MRI
can be well tolerated. We were able to estimate NM
CBR and pigmented NM volumes using a dedicated
brief NM-sensitive sequence with an age-adjusted
threshold. We found a steep increase in both bright-
ness and volume during childhood-adolescence.
Thus, our in vivo ﬁndings are well in line with histo-
logical reports that NM deposition appears to start
at birth or at a very early stage of life,19,20,29,30 with
an almost linear increase of NM-containing neurons
in the ﬁrst 2 to 3 decades of life. Linear ﬁts
explained > 71% of NM contrast variance and about
50% of the variance of NM volume in our cohort,
suggesting a stronger developmental effect on the
degree of pigmentation than the volume of pigmented
SNpc. Our ﬁndings also agree well with earlier stud-
ies showing that the degree of pigmentation of the
SN is greater in the adult brain than in children and
adolescents.29,30
NM is an insoluble complex of pigment, lipid, and
protein found in cytosolic organelles of
catecholaminergic neurons that do not undergo physio-
logical degradation, thereby explaining its accumula-
tion. In fact, NM was proposed to reﬂect a
chronological metric of cumulative metabolic waste.20
Biosynthesis of the melanic component is directly linked
to catecholaminergic metabolism, and in the SN it is
speciﬁcally associated with oxidation of nonvesicular
dopamine.1
Neuromelanin Declines From Middle to
Old Age
In line with the chronometric hypothesis of NM synthe-
sis, a continued linear signal increase would be expected
and has been suggested.31 In contrast, our current study
clearly demonstrates that MRI detected nigral NM bright-
ness and that volume changes little during adulthood and
decay from about the mid-5th decade in healthy aging.
The observed age trajectory of the SNpc NM contrast
shows a remarkable similarity with the largest available
life span postmortem sample,32 as further validation that
neuromelanin content explains the observed MRI con-
trast. A similar quadratic age trajectory, although only
explaining less than 15% of NM contrast, was reported
in the LC in 64 healthy subjects spanning adulthood to
old age.26 The weaker effect may be because of partial
volume effects of the smaller LC, less pigmentation, and
different levels of metals and other chemicals.33 Neverthe-
less, the similarity of the trajectory of signal changes with
signal reduction observed in both the LC26 and the SN in
our study suggests an involutional loss of NM pigment in
catecholaminergic nuclei in old age. Other histological
studies demonstrated that the number of pigmented SN
neurons declines signiﬁcantly, ranging from 28.3% to
66.7% while aging from 20 to 90 years old.21,22,32,34
The discrepant observation of the increase in nigral NM
pigmentation throughout adult life in 1 series of postmor-
tem samples31,35 might be explained by cohort differ-
ences, differences in NM detection methods (as argued by
reference 35), and possible conformational pigment
changes during aging.4 Using our CBR measures, we esti-
mated 4.6% loss per decade of life from 47 years old
over our decade groups, which is consistent with the loss
rate reported in other works.21,22
MRI appearances of preferential contrast over volume
reduction of pigmented SN in old age could be explained
by either NM loss or reduced NM iron content. The latter
is unlikely, as total brain iron and also SN iron are
known to increase with age,24,36 and there is also no evi-
dence for reduced iron-chelating capacity of NM in old
age. Future work is needed to elucidate how the change
of free iron together with reduced ferritin-NM compound
translate into the NM- and iron-sensitive images.37 Taken
together the observed age effect of NM decline from mid-
dle age is most likely a marker of degeneration of dopa-
minergic neurons, thereby offering a window for future
FIG. 3. Contrast-to-noise ratio of the anterior and posterior SN in
healthy participants. Similar relationship patterns of CBR-SN anterior
(green open circles) and CBR-SN posterior (blue open circles) and age
(green and blue curves) are shown. Dashed lines represent 95% conﬁ-
dence intervals. [Color ﬁgure can be viewed at wileyonlinelibrary.com]
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studies into age-related brain stem degeneration and its
link to PD pathogenesis.
Neuromelanin, Iron, and Vulnerability to
Neurodegenerative Disorders
Previous evidence points to an important role of iron in
the normal development of the dopaminergic system and
degeneration.33,38,39 Age-related increase in the concentra-
tion of brain iron was found to be related to increased
blood-brain barrier permeability, neuroinﬂammation, and
redistribution of iron.40,41 The synthesis of NM helps the
sequestration of toxic metals, such as iron overload, which
could exert a neuroprotective effect.2,24,42-44 Conversely,
extracellular NM may be involved in the pathogenesis of
PD by triggering neurodegeneration via an immune-based
pathogenic mechanism.2,45-47 The subregional distribution
difference of NM-bound iron and its possible divergent
age effects might offer an explanation for the link between
NM, iron, and age-related neurodegeneration of brain
stem nuclei.38,48-50 The iron deposition in SN in PD has
been investigated using different MRI techniques. How-
ever, the ﬁndings are not consistent.51-57 This discrepancy
may be ascribed to the incongruence of the deﬁnition of
SN based on different MRI approaches (see review in ref-
erence 58). Recent studies analyzed the iron level in the
SN deﬁned by NM MRI, and they have consistently dem-
onstrated increased T2*-weighted hypointensity in lateral-
ventral SNc in patients. This loss of hyperintensity in the
nigrosome-1, which resembles the swallowtail, was pro-
posed to reﬂect iron deposition and neuromelanin loss
underlying the pathology of Parkinson’s disease.59 Our
ﬁndings of an anterior-posterior gradient in SNpc contrast
with lower CBR in the posterior SN also echoes this previ-
ous imaging and pathological evidence.17,21,51 Impor-
tantly, we found that the NM gradient was present from
an early age and persisted over the life span, suggesting an
age-independent regional effect that may confer resilience
to PD pathology35 and thus support an NM neuroprotec-
tive role. It is noticeable that we also found bigger normal-
ized SN volumes in women compared with men older
than 47 years, which may underpin the high male-to-
female ratio of the prevalence of PD.
Our ﬁndings are broadly in line with a putative neuro-
protective role of NM, but longitudinal in vivo NM MRI
in combination with iron mapping will be needed to fully
elucidate the role of subregional NM and iron content
during healthy aging and early neurodegeneration. An
increasing body of imaging evidence supports the value of
NM MRI as a disease biomarker in Parkinson’s disease.
Our previous results and other studies using NM MRI
have shown a signiﬁcant decrease of neuromelanin-related
signals and/or volume in SN in PD, allowing for higher
discrimination accuracy between PD and age-matched
healthy controls.15,16 Evidence also demonstrated that vol-
ume loss correlated with disease duration and severity.17
Furthermore, preliminary longitudinal ﬁndings suggested
that neuromelanin MRI might be used as an indicator of
disease progression.10 A very recent review recom-
mends that NM MRI may be useful for regularly
screening older participants at risk for PD and for
detecting PD at the preclinical stage.60 Our study
now provides normative ﬁndings across a wide age
span that will facilitate the study of the role of NM
as a risk factor of and in presymptomatic PD and as
a mechanistic outcome marker in future NM and
iron-targeted interventions.
Strength, Implications, and Limitations
Our study used an optimized brief (less than
4 minutes) MRI protocol for noninvasive in vivo
mapping of neuromelanin-sensitive signals. This is
the ﬁrst comprehensive life span study of the NM
MR signal in healthy subjects in vivo. There are a
few limitations to this retrospective and cross-
sectional MRI study. We cannot exclude the possibil-
ity of some of the older participants having presymp-
tomatic neurodegenerative diseases, and only 66.7%
of those > 47 years old underwent cognitive testing
and clinical screening, whereas others self-reported
their health and cognition status.
Conclusions
We describe a strong nonlinear age effect on brain
stem pigmentation, with an inverted U-shaped associa-
tion providing the ﬁrst detailed trajectory of MR-
detectable brain stem pigmentation and depigmentation
from childhood to old age. Our fast protocol makes it
possible to investigate the role of NM in brain develop-
ment and to longitudinally assess risk and moderator
factors of physiological and pathological brain stem
depigmentation, shedding light on the putative neuro-
protective and neurotoxic effects of NM and iron.
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